

# Emcure

Date: August 24, 2017

To,

1. **Gilead Sciences, Inc.**

333 Lakeside Drive, Foster City  
California 94404, USA

2. **Medicines Patent Pool**

Chemin Louis-Dunant 17  
1202 Geneva, Switzerland

**Sub:** Termination of Elvitegravir (EVG)

**Ref:** License Agreement dated March 15, 2016, executed by and between Gilead Sciences, Inc., the Medicines Patent Pool and Emcure Pharmaceuticals Limited ("**Agreement**").

Dear Sir/Madam,


In accordance with section 10.5 of the above License Agreement, Emcure Pharmaceuticals Limited hereby provides notice of termination of the license for Elvitegravir (EVG) effective immediately.

In alignment with changes in WHO-ARV guidelines we are not pursuing EVG formulation development and hence request exclusion/termination of Elvitegravir (EVG) from the Agreement

We look forward to a fruitful and collaborative relationship with Gilead Science and the Medicines Patent Pool.

Yours Sincerely,

For Emcure Pharmaceuticals Limited



Name: Sanjay Mehta

Designation: President-Commercial



Rajesh Reddy

## Emcure Pharmaceuticals Limited

Registered Office : Emcure House, T-184, M.I.D.C., Bhosari, Pune - 411 026. INDIA  
Phone Nos. : + 91 20 - 27120084, 30610000, 40700000 Fax No. : 91 20 - 30610111  
E-mail : corporate@emcure.co.in CIN : U24231PN1981PLC024251